SCHEMBL29409118

SCHEMBL29409118

CC(C)(C)OC(=O)NC12CC(C(=O)NCC(=O)c3ccc(Cl)cc3)(C1)C2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ MAPT P10636 2/20 0.41
▸ DRD2 P14416 5/20 0.40
▸ TSHR P16473 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ PPARG P37231 1/20 0.39
▸ PPARA Q07869 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ATF4 P18848 1/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ DPP8 Q6V1X1 2/20 0.36
▸ DPP9 Q86TI2 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29409005 0.85 DPP8 (0.40) GAAALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL29435970 0.85 DPP9 (0.44) GAAALDH1A1MAPTDRD2TSHR
SCHEMBL22614119 0.82 ALDH1A1 (0.44) ALDH1A1MAPTHTTATF4MEN1
SCHEMBL14830379 0.80 ALDH1A1 (0.52) GAAALDH1A1MAPTDRD2TSHR
SCHEMBL29408889 0.79 PPARG (0.41) GAAALDH1A1MAPTDRD2TSHR
SCHEMBL31501042 0.76 ATF4 (0.57) GAAALDH1A1TSHRATF4MEN1
SCHEMBL29525089 0.74 DRD2 (0.47) GAAALDH1A1MAPTDRD2PPARG
SCHEMBL30445754 0.72 GHSR (0.43) GAAALDH1A1DRD2SMN1; SMN2NPSR1
SCHEMBL202972 0.72 CTSS (0.44) ALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL23332808 0.71 ATF4 (0.76) ALDH1A1TSHRNPSR1ATF4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2025-05-08 — — US disclosed
EP-4237413-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2023-09-06 — — EP disclosed
WO-2022094244-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-05-05 — — WO disclosed
CN-114206848-A Substituted cycloalkyl compounds as modulators of integrated stress pathways 卡里科生命科学有限责任公司 2022-03-18 — — CN disclosed
EP-3962906-A1 SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2022-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 GAA 1937/4885ALDH1A1 2882/4885MAPT 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback